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ABSTRACT 
Background: The relationship between dietary sodium and mortality is poorly characterized. 
Recent reviews and studies offer contradictory results.  
Purpose: To compare the benefits and harms of dietary sodium reduction.  
Data Sources: MEDLINE from inception through April 2012, English language restriction.  
Study Selection: Prospective cohort studies, randomized controlled trials, and cluster 
randomized controlled trials that quantitatively compare a low versus high sodium diet with 
follow up greater than 2.5 years. Secondary prevention studies are excluded.  
Data Extraction: One reviewer selected studies for inclusion. One reviewer abstracted data 
with second checking by another reviewer. Two reviewer independently assessed study quality.  
Data Synthesis: Twenty studies, 1 cluster randomized controlled trial (fair quality), 4 
randomized controlled trials (2 good quality, 2 fair quality), and 15 prospective cohort studies (all 
fair quality) met inclusion criteria. 1 study was excluded for a high risk of bias. Included studies 
contributed a total of 248,895 unique individuals for analysis. 10 studies had a follow-up greater 
than 10 years. Dietary sodium reduction had a pooled all cause mortality HR [95% CI] of 1.00 
[0.92 to 1.07], a pooled cardiovascular mortality HR [95% CI] of 0.95 [0.76 to 1.15], a pooled 
cardiovascular RR [95% CI] of 1.00 [0.77 to 1.12] at study end, a pooled stroke mortality HR 
[95%] of 0.77 [0.59 to 0.97], and a pooled stroke HR [95% CI] of 0.90 [0.84 to 0.95]. Studies 
with a baseline dietary sodium above 4000 mg per day showed a benefit of sodium reduction 
with a pooled all cause mortality HR [95% CI] of 0.90 [0.82 to 0.98]. All results have a low 
strength of evidence.  
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Limitations: A majority of studies are fair quality cohort studies prone to confounding. There 
are few high quality studies with enough power to drive conclusions. Interstudy variability is 
high. These results do not apply to a secondary prevention population.  
Conclusions: Reducing dietary sodium did not improve all cause mortality or cardiovascular 
disease risk. Sodium reduction does appear to decrease stroke risk. A dose response 
relationship between dietary sodium and outcomes is needed to identify an optimal level of 
sodium consumption.   
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INTRODUCTION 
Current recommendations for daily dietary sodium consumption 
Table 1. Summary of Dietary Sodium Intake Recommendations in the United States 
Organization mg/day 
United States Department of 
Agriculture1 
< 2300a 
< 1500b 
American Heart Association2 < 1500 
Joint National Committee on 
Prevention,  
Detection, Evaluation, and Treatment 
of High Blood Pressure3 
< 2400 
Institute of Medicine4  
 Tolerable upper intake 
 Adequate intake 
 
2300 
1500c 
1300d 
1200e 
  aHealthy adults ages 19-50. bAges 51+, hypertension,  
  African Americans. cAdults ages 19-50. dAdults ages 51-70.  
  eAdults ages 71+.  
  
 Recommended levels of dietary sodium consumption range from less than 1200 mg/day 
to less than 2400 mg/day. The methodology used to derive these recommended values varies. 
The United States Department of Agriculture (USDA) bases its recommendations on an Institute 
of Medicine’s (IOM) report.1 The IOM semi-systematically reviewed evidence and found that 
2300 mg/day of dietary sodium is the tolerable upper intake for adults. The IOM found a 
progressive and direct relationship between blood pressure and dietary sodium, and that this 
relationship becomes more robust at sodium intakes above 2300 mg/day. Notably however, the 
IOM does not make a recommendation for daily dietary sodium consumption. The IOM found 
inadequate evidence to recommend an ideal dietary sodium level because morbidity outcomes 
at multiple levels of sodium consumption were not available.4 Instead the IOM provides an 
“adequate intake”, which represents that amount of daily sodium required to meet the “Intake 
level to cover possible daily losses, provide adequate intakes of other nutrients, and maintain 
normal function”(pg.12).4 The IOM specifically notes that its adequate intake and tolerable upper 
intake values do not represent recommendations.  
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 The American Heart Association (AHA) bases its recommendation on USDA, IOM, and 
Food and Drug Administration (FDA) reports.2 Recently, an FDA report stated that 69.2% of US 
adults meet the USDA criteria recommending less than 1500 mg/day dietary sodium.5 Since 
such a large portion of the US population meet USDA criteria for less than 1500 mg/day dietary 
sodium, the AHA set 1500 mg/day as their standard.  
 The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure, Seventh Report (JNC-7) dietary sodium guideline is based on a single 
narrative review that primarily assesses the relationship between dietary sodium and blood 
pressure.3,6 The JNC-7 sodium guideline only considers two prospective cohort studies with 
mortality or cardiovascular disease (CVD) as outcomes.   
 Overall, I did not find strong evidence to support current guidelines for daily dietary 
sodium consumption in the United States. No recommendation systematically reviews dietary 
sodium in relation to morbidity outcomes. A majority of the recommendations are ultimately 
based on a single IOM report. However, the IOM report itself found insufficient evidence to 
make a recommendation. Since the IOM could not determine an ideal level of sodium 
consumption, they reported a minimum level of sodium consumption (1500 mg/day) that would 
not cause undue restriction in achieving an otherwise nutritious diet. The IOM’s tolerable upper 
sodium intake (2300 mg/day) relies exclusively on the relationship between dietary sodium and 
an intermediate outcome – blood pressure.  
 Policies and guidelines to reduce dietary sodium consumption are widespread around 
the world. Finland currently recommends 5 g of sodium per day.7 Canada recommends between 
1.2-2.3 g per day.8 Australia and New Zealand recommend 1.6 g per day.9 The United Kingdom 
recommends 2 g per day.10 Numerous international organizations, professional societies, and 
initiatives recommend decreasing sodium consumption on a population scale11-16. 
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Dietary sodium levels in the United States and around the world 
Table 2. 24-Hour Sodium Excretion Around the World 
Rank Country mg/day 
 
Rank Country mg/day 
1 
Republic of 
Korea 4798 
 
15 Russian Federation 3712 
2 China 4744 
 
16 Argentina 3581 
3 Colombia 4636 
 
17 United Kingdom 3497 
4 Hungary 4559 
 
18 Netherlands 3464 
5 Poland 4357 
 
19 Belgium 3316 
6 Japan 4307 
 
20 Mexico 3309 
7 India 4190 
 
21 Taiwan 3244 
8 Portugal 4178 
 
22 Denmark 3221 
9 Spain 4113 
 
23 Iceland 3179 
10 Canada 4086 
 
24 USA 3117 
11 Italy 4034 
 
25 
Trinidad and 
Tobago 2684 
12 Malta 3904 
 
26 Kenya 1309 
13 Finland 3738 
 
27 Papua New Guinea 854 
14 Germany 3732 
 
28 
Brazil (rural 
Amazon) 152 
 
 To put dietary sodium consumption in the United States in perspective, I adapted data 
from the World Health Organization (WHO) INTERSALT study to show mean consumption 
around the world (Table 2).17,18 The INTERSALT study, sought to associate urinary sodium 
excretion with blood pressure in 52 populations around the world. The INTERSALT study did 
not set out to take nationally representative samples of dietary sodium. However, it is a large 
and methodologically standardized study of 10,079 people that reports 24-hour urine sodium 
excretion in multiple populations around the world. A separate WHO report analyzes 37 studies 
that measure sodium consumption in individual countries and finds wide variation within and 
between countries depending on survey methodology.17 The IOM estimates the average 
American consumes 3400 mg of sodium per day, corroborating the validity of INTERSALT 
results.4 Thus, the INTERSALT study represents the best standardized measure of sodium 
consumption around the world.  
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Dietary Sodium and Blood Pressure 
  
Figure 1. Correlation between average daily NaCl intake and incidence of hypertension.  
Figure 1 in: Dahl LK. Possible role of salt intake in the development of essential hypertension. 
1960. Found in International journal of epidemiology. Oct 2005;34(5):967-972; discussion 972-
964, 975-968.  
 In 1960 L.K. Dahl published a cross-sectional study that showed a direct correlation 
between dietary sodium and blood pressure in 5 Japanese and American populations (Figure 
1).19,20 Notably, this Dahl graph measures grams of salt as opposed to sodium. To convert 
grams of salt to grams of sodium, divide by 2.5. Thus, sodium intake in the Dahl study 
approximately ranged from 1200mg in Alaskan Eskimos to 10,800 mg in Northern Japanese - a 
very wide range.  
 Since the Dahl study, numerous studies and subsequent meta-analysis confirm a 
positive relationship between dietary sodium and blood pressure.21-29 The largest and most 
recent systematic review and meta-analysis of 167 randomized controlled trials (RCTs) found 
that a 2800 mg/day reduction in sodium decreases systolic blood pressure by 1.27 to 10.21 
mmHg depending on race and initial systolic blood pressure.30 
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Dietary Sodium and Morbidity/Mortality 
 The relationship between dietary sodium and morbidity/mortality is unclear. The 
CARDIAC study used a cross-sectional analysis of 2462 male participants in 16 different 
countries and found dietary sodium to be positively associated with stroke incidence with an R-
squared of 0.67 (p<0.01).31 Interestingly, the CARDIAC study found an inverse relationship 
between dietary sodium and ischemic heart disease with an R-squared of -0.46 (p<0.05).31 
Another cross-sectional study used dietary sodium from the INTERSALT study, and mortality 
tables from the WHO, to find a similar positive correlation between stroke and dietary sodium.32 
In Finland, a 30 year campaign to reduce sodium intake has been mirrored by similar reductions 
in coronary heart disease and stroke mortality (figure 2).33 However, the Finland study fails to 
address confounding caused by other healthcare advances during the same time period. 
Furthermore, all 3 of these studies show correlation, but none can effectively prove causation.   
 
Figure 2. Cardiovascular Mortality and Salt Intake Trends over 30-years in Finland. As salt 
intake decrease, cardiac and stroke mortality decreases to a similar degree. Adapted from: 
Karppanen H, Mervaala E. Sodium intake and hypertension. Progress in Cardiovascular 
Diseases. Sep-Oct 2006;49(2):59-75. 
10 
 
 
 Recently, 2 systematic reviews and meta-analysis of prospective dietary sodium 
reduction studies have come to different conclusions. The first review, looked at 13 prospective 
studies with a total of 177,025 people at a minimum of 3 years follow-up and found that elevated 
sodium increased the relative risk of stroke of 1.23 [95% CI 1.06-1.43] and the relative risk of 
cardiovascular disease of 1.17 [95% CI 1.02-1.34].34 However, a second recent review of 7 
RCTs with a total of 6489 people at a minimum of 6 months follow-up failed to find any 
significant association between dietary sodium, and cardiovascular mortality.35 Possible reasons 
for this discrepancy include short follow up and low statistical power in the second study, since it 
only used RCTs. However, it is also possible that low sodium diets have harmful side effects 
that counteract the beneficial effects of lower blood pressure.  
Harms of Reducing Dietary Sodium 
 The harms of reduced sodium diets are poorly described. Historically, dietary sodium 
studies have focused on blood pressure as the outcome of interest. At all levels, blood pressure 
is associated with a progressively increased risk of vascular death, starting at 115/75 mmHg.36 
The harms of low blood pressure depend on the clinical presentation of an individual. Since 
nearly all levels of blood pressure are associated with an increased risk of vascular death, 
dietary sodium studies with blood pressure as an outcome cannot detect harms associated with 
a low sodium diet. Only prospective morbidity and mortality studies can elucidate potential 
harms associated with a low sodium diet.  
 Several recent prospective cohort studies have indicated that low sodium diets may be 
associated with increased cardiovascular disease.37,38 Another study provides a theoretical 
framework around which low sodium diets may cause harm. This study systematically reviewed 
low sodium diets and associated low sodium with statistically significant increases in renin, 
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aldosterone, norepinephrine, epinephrine, total cholesterol, and triglycerides.30 Increases in 
these lipids and hormones could negate the benefit conferred by lower blood pressure.  
Measuring Dietary Sodium 
 
 The gold standard for estimation of dietary sodium is a 24-hour urine collection. 
Frequently, urine creatinine or PABA is used to ensure a complete sample has been collected. 
However, 24-hour urine sodium underestimates dietary sodium consumption by approximately 
15% due to loses in sweat and feces.39  
 Many studies, especially large studies over long periods of time, do not gather 24-hour 
urine sodium for cost of logistical reasons. These studies often rely on some type of food 
frequency questionnaire (FFQ) or 24-hour dietary recall. A recent review indicates FFQs and 
24-hour dietary recall typically report 22% to 50% less sodium consumption than a 24-hour 
urine sodium.40 To optimally estimate dietary sodium, surveys should be conducted over several 
days.41 Furthermore, survey patients should be masked to decrease social desirability biases.42 
Purpose of This Systematic Review 
 The relationship between dietary sodium consumption and morbidity/mortality is poorly 
understood. Numerous public health campaigns and recommendations are based on the 
relationship between dietary sodium and blood pressure. Given that recent studies and meta-
analysis fail to find benefit in sodium reduction indicates that harms of sodium reduction may 
have been overlooked. This review will systematically search, appraise, and meta-analyze 
prospective cohort, randomized controlled trials, and cluster randomized controlled trials that 
compare dietary sodium to morbidity/mortality in a general population.  
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METHODS: 
Study Selection:   
Table 3: Study Eligibility Criteria (PICOTS) 
Population (s) Population based sample of adults greater than or equal to 18 years old. 
Studies focusing exclusively on secondary prevention were excluded.  
Interventions Dietary sodium should be measured by any quantitative means. 
Qualitative forms of sodium estimation were excluded.   
Comparators Study should provide categorically different levels of sodium consumption 
for comparison, or provide sodium consumption as a continuous variable.   
Outcomes All-cause mortality is the primary outcome. Secondary outcomes include: 
cardiovascular disease mortality, cardiovascular disease, stroke mortality, 
and stroke.  
Timing Outcomes should be assessed at least at 2.5 years of follow-up.   
Settings Included studies are population based without geographic limits 
Study Designs Relevant study designs for the review are prospective cohort studies, 
randomized controlled trials, and cluster randomized trials.  
  
 Study inclusion criteria for this review are outlined in table 3. This review aims to focus 
on primary prevention. However, no study deals exclusively with an asymptomatic population. 
Therefore, this review’s inclusion criteria include any sample of adults greater than or equal to 
18 years old. However, this review excludes any studies that focus exclusively on secondary 
prevention. For example, an included study population may have a component of people with 
congestive heart failure. However, a study exclusively of people with congestive heart failure 
would be excluded.  
 This review considers all forms of dietary sodium estimation that produce a quantitative 
value. However, the method of sodium estimation is evaluated in the overall quality rating of the 
study. Examples of high quality dietary sodium estimation include: multiple 24-hour urine 
sodium samples, a single 24-hour urine sodium, and comprehensive dietary interviews. Passive 
FFQs and 24-hour dietary recall are less robust forms of dietary sodium estimation. I excluded 
qualitative surrogates for sodium consumption, like frequency of salt shaker use or frequency of 
soup consumption.  
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 This review uses all-cause mortality as the primary outcome. Other outcomes of interest 
include: CVD, CVD mortality, stroke, and stroke mortality. All-cause mortality was chosen as the 
primary outcome because it does not have classification biases. CVD and stroke outcomes 
often have unreliable and variable reporting schemes. Included studies were partially graded on 
the validity of outcomes measurements. International Statistical Classification of Disease (ICD) 
were considered a less than optimal method of reporting outcomes. The best outcomes 
measurements had specific criteria described in applicable methods sections.  
 This review considers all studies with greater than or equal to 2.5 years of follow-up. 
While any health benefit of sodium reduction will likely take more than 2.5 years, such a short 
follow-up time allows for the identification of any short term harms of sodium reduction. This 
review aims to compare short term follow-up to long term follow-up the see if the harm/benefit 
balance of sodium reduction changes over time.  
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Literature Search: 
 To identify articles, I searched MEDLINE from inception to April 2012 with the strategy 
outlined in table 4. The search was limited to human subjects and English language articles. 
Furthermore, I manually searched the references of pertinent reviews and studies to find any 
relevant articles missed by the electronic search. All citations were imported into EndNote X5 
(Thompson Reuters, New York, NY). All titles and abstracts identified through the literature 
search were reviewed for eligibility against inclusion criteria. The full text of studies was 
reviewed against the inclusion and exclusion criteria if the title or abstract provided insufficient 
information. Exclusion criteria, as outlined in figure 3, include: qualitative dietary sodium 
measurement, outcomes not under review, lack of a comparison group, retrospective studies, 
case-control studies, and outcomes assessments less than 2.5 years.  
Table 4: Search Strategy with Resulting Number of Identified Articles 
Search 
Number 
Search Term Number of 
Articles 
Yielded 
1 “Diet, Sodium-Restricted”[Mesh] 5181 
2 “Sodium, Dietary”[Mesh] 7056 
3 “Sodium Chloride, Dietary”[Mesh] 3383 
4 Sodium[Mesh] 99290 
5 Mortality[Mesh] 245618 
6 “Myocardial Infarction”[Mesh] 135265 
7 “Heart Arrest”[Mesh] 29839 
8 “Heart Failure”[Mesh] 76366 
9 “Cerebrovascular Disorders”[Mesh] 246291 
10 “Peripheral Vascular Diseases”[Mesh] 41751 
11 Stroke[Mesh] 68778 
12 Search #1 OR #2 OR #3 OR #4 102612 
13 Search #5 OR #6 OR #7 OR #8 OR #9 OR #10 
OR #11 
731870 
14 Search #12 AND #13 2843 
15 Search #12 AND #13 Limits: Humans, English 1380 
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Figure 3. Exclusion criteria for studies found by literature search.  
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Data Abstraction:  
 For studies that met inclusion and exclusion criteria, data was extracted in evidence 
tables that included information on: study population, study design, methodology, study quality, 
interventions, and results. A single reviewer abstracted data, with second checking by a second 
reviewer. Results were recorded by intention-to-treat when possible. All data was compiled into 
tables using Microsoft Excel software.  
Quality Assessment:  
 Good, fair, and poor ratings developed by the United States Preventive Services Task 
Force (USPSTF) and the University of York Center for Reviews and Dissemination were used to 
assess the internal validity of individual studies included in this systematic review.43,44 A “good” 
study has results with minimal risk of bias. A “fair” study has some risks of bias, but the potential 
bias is not great enough to invalidate findings. For example, a study that has a medium risk of 
bias, but shows a large magnitude of effect would receive a fair rating. A “poor” study has bias 
to the point that findings become unreliable. A poor study may have a single “fatal” 
methodological flaw or multiple minor flaws that cumulatively increase the risk for bias. Studies 
receiving a “poor” rating were excluded from analysis. Table 5 lists criteria used to grade study 
quality. “Good” quality studies had ideal responses to each criteria, or all but 1 criteria. All 
studies were independently assessed by two reviewers.  Any disagreements were resolved 
through consensus discussion or third party mediation.  
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Table 5. Study Quality Assessment Criteria 
Quality Criteria for Prospective Cohort 
Studies 
 
Quality Criteria for Randomized Trials 
1. Is the study design prospective? 
 
1. Did the authors report the study was 
randomized? 
2. Were groups recruited from the same source 
population? 
 
2. Was randomization adequate? 
3. Were subjects in both groups recruited over 
the same time period? 
 
3. Was allocation concealment 
adequate? 
4.  Were inclusion and exclusion criteria equally 
applied in both groups? 
 
4. Were groups similar at baseline? 
5. Was an attempt made to blind the study 
participants? 
 
5. Were outcome assessors masked? 
6. Was an attempt made to blind the outcome 
assessors? 
 
6. Were care providers masked? 
7. Was the time of follow-up equal in both 
groups? 
 
7. Were patients masked? 
8. Were differences between groups taken into 
account in the statistical analysis?  
 
8. % completed follow-up 
9. Was confounding adequately accounted for 
either through study design or statistical 
analysis? 
 
9. Was overall attrition ≥20%?  
10. % lost to follow up 
 
10. Was differential attrition ≥15%? 
11. Was overall attrition ≥20%?  
 
11. Did the study use ITT analyses?  
12. Was differential attrition ≥15%? 
 
12. Method of handling dropouts 
13. Were any participants who started the trial 
excluded from the analysis?  
 
13. Was dietary sodium measurement 
equal, valid, and reliable? 
14. Method of handling dropouts 
 
14. Was dietary sodium measured by 
multiple 24-hour urine samples? 
15. Was dietary sodium measurement equal, 
valid, and reliable? 
 
15. Were outcome measures equal, valid 
and reliable? 
16. Was dietary sodium measured by multiple 
24-hour urine samples? 
  17. Were outcome measures equal, valid and 
reliable? 
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Data Synthesis:  
 When a sufficient number of studies reported an outcome, meta-analysis was 
performed. Evaluation of study heterogeneity was performed in accordance with Agency of 
Healthcare Research and Quality (AHRQ) guidelines by qualitatively looking for similarities and 
differences among individual studies according to PICOTS criteria.45 When meta-analysis was 
not appropriate, data was synthesized through qualitative evaluation.  
 Meta-analysis utilized random-effects models to estimate pooled hazard ratios or risk 
ratios for all-cause mortality, CVD mortality, CVD, stroke mortality, and stroke.46 This review 
preferentially used HRs associated with dietary sodium reported as a continuous variable. If 
baseline dietary sodium was reported as a categorical variable, a composite hazard ratio was 
calculated for the study before inclusion into the meta-analysis. CVD analysis lacked sufficient 
HR data, thus RR was used for CVD meta-analysis. Forest plots graphically represent individual 
studies of the meta-analysis.47 I used the I-squared statistic to measure heterogeneity between 
studies.48,49 An I-squared from 0 to 40 percent may signify minimal heterogeneity, from 30 to 60 
percent may signify moderate heterogeneity, from 50 to 90 percent may represent substantial 
heterogeneity, and greater than or equal to 75 percent typically signifies considerable 
heterogeneity.50 The overall importance of an I-squared value depends on the magnitude and 
direction of the effect size and on strength of evidence evaluations. This study explores 
heterogeneity through subgroup analysis of study design, population demographics, and 
variations intervention. This report uses Stata version 12.0 for all quantitative analysis 
(StataCorp LP,College Station, TX).  
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Grading Strength of Evidence: 
I graded the strength of the overall body of evidence according the AHRQ guidelines.51 Strength 
of evidence evaluates the overall body of evidence in five domains: risk of bias, consistency, 
directness, precision, and confounding. Risk of bias evaluates study type and the aggregate 
study internal validity. Consistency is the degree and magnitude of agreement amongst study 
effect sizes. Directness scores the degree to which the evidence relates to a health outcomes. 
Precision evaluates the degree of certainty surrounding a given outcome. Confounding 
assesses the plausibility of confounding to explain observed effects. Risk of bias, consistency, 
directness, precision, and confounding are used to generate an overall strength of evidence 
grade, as outlined in table 5.  
Table 5. Definition of Strength of Evidence Grades51 
Grade Definition 
High High confidence that the evidence reflects the true effect. Further research is 
very unlikely to change our confidence in the estimate of effect. 
Moderate Moderate confidence that the evidence reflects the true effect. Further research 
may change our confidence in the estimate of the effect and may change the 
estimate. 
Low Low confidence that the evidence reflects the true effect. Further research is 
likely to change our confidence in the estimate of the effect and is likely to 
change the estimate. 
Insufficient Evidence either is unavailable or does not permit estimation of an effect. 
 
Applicability Assessment: 
I assessed applicability of the evidence following established guidelines.52  The applicability 
assessment uses the PICOTS framework to determine the external validity of the systematic 
review results. Some factors identified a priori that may limit the applicability of evidence 
included the following: age of enrolled populations, sex of enrolled populations, baseline dietary 
sodium, baseline dietary potassium, baseline blood pressure, baseline BMI, diabetes status, 
and smoking status.   
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RESULTS 
Search Results: 
The literature search identified 1389 articles. I assessed 81 full-text articles against the inclusion 
and exclusion criteria. Dual reviewers evaluated 20 articles, all of which received a “good” or 
“fair” quality rating. Figure 4 outlines the search results.  
 
Figure 4. Disposition of records identified through literature search. A total of 1389 records were 
screened, ultimately resulting in 20 studies included in the synthesis of this review.   
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Characteristics of Included Studies: 
 Table 6 summarizes the characteristics of the 20 studies that met inclusion criteria. One 
cluster randomized controlled trial (fair quality), 4 randomized controlled trials (2 good quality, 2 
fair quality), and 15 prospective cohort studies (all fair quality) met inclusion criteria. These 
studies include a total of 248,895 unique individuals (two studies report on the same cohort 
populations and are thus excluded from the total population calculation53,54). One study was 
excluded due to a high risk for bias.55 
 Two population cohorts have multiple publications. Both Alderman et al.-199856 and He 
et al.-199954 report on the National Health and Nutrition Examination Survey I (NHANES I) study 
cohort. Alderman et al.-199856 report on the entire NHANES I cohort, while He et al.-199954 
dichotomize outcomes based on BMI. He et al.-199954 provide outcomes between overweight 
and non-overweight individuals, defining overweight as a body mass index of 27.8 kg/m2 or 
higher for men and 27.3 kg/m2 or higher for women.  
 Cohen et al.-200853 and Yang et al.-201157 both report on the National Health and 
Nutrition Examination Survey I (NHANES III) study cohort. The two reports differ because 
Cohen et al.-200853 analyses adults over age 30, while Yang et al.-201157 analyses adults over 
age 20. Furthermore, the Yang et al.-201157 has a slightly longer follow-up period.  
 Cook et al.-200758 reports on both the Trial of Hypertension Prevention I (TOHP I) and 
Trial of Hypertension Prevention II (TOHP II). TOHP I randomizes individuals to either an 
intensive dietary sodium reduction program or usual care. TOHP II presents results such that 
the intervention group received a program to reduce both weight and sodium intake, while the 
control group perused weight loss only.  
 About half of the studies were conducted in the United States, with other studies 
conducted in the Finland59-61, Japan62-64, Taiwan65, Australia66, United Kingdom67 or in multiple 
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European countries37. Sample sizes ranged from 587 to 77,500 people. Most trials enrolled 
representative population samples, however three studies report on high risk populations. Ekinci 
et al.-201166 restrict their study to patients with diabetes mellitus type 2 (DM2). Thomas et al.-
201160 only report on patients with diabetes mellitus types 1 (DM1). Larsson et al.-200861 focus 
exclusively on male smokers. Follow-up periods ranged from 2.5 to 19 years. Mean baseline 
dietary sodium (mg/24 hrs) ranged from 2022 to 5416. Female representation ranged from 29% 
to 64% of respective study populations. Mean age ranged widely between studies from 39 to 75 
years. Baseline mean systolic blood pressure (mmHg) ranged from 121 to 145.  
 Studies conducted outside in the United States (excluding Larsson et al.-200861 which 
lacks a mean value) had a total of 210,783 participants and mean dietary sodium of 4104 
mg/24hrs. Studies conducted inside the United States (excluding He et al.-199954 and Cohen et 
al.-200853 due to study population duplication) had a total of 38,112 participants and a mean 
dietary sodium of 2954 mg/24 hrs. The 3 studies conducted in Japan had a total of 165,329 
participants and a mean dietary sodium of 4109 mg/24 hrs. The 2 Finland studies with a mean 
composite baseline sodium had a total of 5243 participants and a mean dietary sodium of 3854 
mg/24 hrs. Thus, baseline dietary sodium consumption for included studies in the United States, 
Japan, and Finland roughly agree with INTERSALT world sodium estimates.17,18  
 Included studies measure dietary sodium in a variety of ways. The following summarizes 
ways used to calculate dietary sodium consumption in order of relative methodological strength. 
One cluster randomized trial directly controlled sodium intake at residential veterans’ kitchens in 
Taiwan.65 Three studies used multiple 24-hour urine collections.58,66 Five studies used a single 
24-hour urine sample at baseline.37,59,60,67,68 One study used a single baseline overnight urine 
sample corroborated by a passive 24-hour dietary recall.69 Five studies used an active 24-hour 
dietary recall administered by a trained interviewer.53,54,56,57,70 One study used a passive 24-hour 
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dietary recall where the patient was not aided by any study personel.63 Four studies used some 
form of food frequency questionnaire (FFQ).61,62,64,71 
 Fourteen studies report all-cause mortality. All-cause mortality is typically determined 
from death certificates or national death registry. Twelve studies report CVD mortality. Five 
studies report stroke mortality. Five studies report both fatal and non-fatal CVD. Six studies 
report both fatal and non-fatal strokes. All studies identify CVD and stroke through ICD codes, 
with the exception of Whelton et al.-199868 who utilized a masked committee to prospectively 
evaluate medical records when an event occurred.  
 Dual reviewers excluded a 1985 prospective cohort study due to a high risk of bias.55 
The study measured dietary sodium through passive 24-hour dietary recall, which we consider 
to be a weak method for estimation. Furthermore, follow-up time between study groups was 
unclear, the amount of data lost to follow-up was not described, and the study did not attempt to 
address confounding.  
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Table 6: Characteristics of Included Studies 
Study 
Study 
Type N 
Follow 
up 
(yrs) 
Baseline 
Dietary 
Sodium 
(mg/d) 
Method of 
Sodium 
Estimation 
Mean 
Age 
(yrs) 
% 
Female 
SBP 
(mmHg) 
Risk of 
Bias 
HPT group, 
1990
69
 
RCT 587 3 3449 Urine sample 39 37 124 Low 
Tunstall-
Pedoe et al., 
1997
67
 
P. 
Cohort 
7354 7.8 3874 
24 hour urine 
Range: 
40 to 59 
49 - Moderate 
Alderman et 
al., 1998
56
 
P. 
Cohort 
11,346 Range: 
15 to 
20 
2022 
Active recall 
50 61 135 Moderate 
Whelton et 
al., 1998
68
 
RCT 975 2.5 3415 24 hour urine 67 48 129 Low 
He et al., 
1999
54
 
P. 
Cohort 
9485 19 2063 Active recall 49 61 134 Moderate 
Tuomilehto 
et al., 2001
59
 
P. 
Cohort 
2436 Range: 
8 to 13 
4322 24 hour urine 46 52 143 Moderate 
Nagata et 
al., 2004
62
 
P. 
Cohort 
29,099 7 5416 Questionnaire 55 54 - Moderate 
Chang et al., 
2006
65
 
Cluster 
RCT 
1982 2.6 5200 Controlled 
intake 
75 - 131 Moderate 
Cohen et al., 
2006
70
 
P. 
Cohort 
7154 13.7 2718 Active recall 48 53 127 Moderate 
Cook et al., 
2007
58
 
RCT 744 15 3577 Multiple 24 
hour urine 
43 29 125 Moderate, 
Low 
Cook et al., 
2007
58
 
RCT 2382 10 4223 Multiple 24 
hour urine 
44 34 127 Moderate, 
Low 
Cohen et al., 
2008
53
 
P. 
Cohort 
8699 8.7 3230 Active recall 48 55 121 Moderate 
Larsson et 
al., 2008
61
 
P. 
Cohort 
26,556 13.6 Range: 3822 to 
5983 
Questionnaire Range: 
57 to 58 
0  142 Moderate 
Umesawa et 
al., 2008 
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P. 
Cohort 
58,730 12.7 2101 Passive recall 56 61 - Moderate 
Takachi et 
al., 2010
64
 
P. 
Cohort 
77,500 7.7 5140 Questionnaire 57 54 - Moderate 
Ekinci et al., 
2011
64
 
P. 
Cohort 
638 Median
: 9.9 
4230 Multiple 24 
hour urine 
64 44 140 Moderate 
Stolarz-
Skrzypck et 
al., 2011
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P. 
Cohort 
3681 Median
: 7.9 
4092 
24 hour urine 
41 53 125 Moderate 
Thomas et 
al., 2011
60
 
P. 
Cohort 
2807 Median
: 10 
3448 24 hour urine 39 49 133 Moderate 
Yang et al., 
2011 
P. 
Cohort 
12,267 Median
: 14.8 
3594 Active recall Age < 
60: 76% 
Age ≥ 
60: 24% 
52 Male: 
< 125: 62.6 
≥ 125: 37.4 
Female:  
< 125: 74.6 
≥ 125:  24.4 
Moderate 
Gardener et 
al., 2012
71
 
P. 
Cohort 
2657 10 3031 Questionnaire 69 64 145 Moderate 
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All Cause Mortality:   
 Meta-analysis finds that sodium reduction does not improve all cause mortality risk 
(figure 5). Meta-analysis of 10 studies, that included 49,984 people, found a pooled HR [95% CI] 
of 1.00 [0.92 to 1.07] for sodium reduction. The meta-analysis had a moderate amount of 
variability indicated by I-squared of 64.9%. However, removing any one study does not change 
results.  
 Four studies were not included in the meta-analysis. He et al.-199954 was not included 
because it is a subgroup analysis of the same population that Alderman et al, 199856 reports. 
Cohen et al.-200853 reports on the same population as Yang et al.-201157. Cohen et al.-200853 
was not included because it has more restrictive study inclusion criteria, and has a shorter 
follow-up period. The Hypertension Prevention Trial69 and Thomas et. al.-201160 was not 
included because they do not provide enough data to make a hazard ratio. Substitution of these 
studies into the meta-analysis and qualitative evaluation of these studies does not change 
results.  
 Organizing data according to: method of sodium estimation, age, length of follow up, and 
magnitude of sodium reduction does not reveal any trends (supplemental figures 1-4). 
Stratifying data by RCTs versus prospective cohort studies does not change results.  
 Since the harms of high dietary sodium likely cause harm through elevated blood 
pressure, adjusting cohort studies for baseline blood pressure could negate the positive benefits 
of a low sodium diet. Studies that adjusted baseline blood pressure were compared to studies 
that did not adjust for baseline blood pressure (supplemental figure 5). RCTs were considered 
to have unadjusted blood pressures because RCT interventions can subsequently change 
intervention blood pressures after the trial begins. Results from studies that adjust for baseline 
blood pressure do not differ from studies that do not. However, if the Tunstall-Pedoe el al.-
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199767 study was removed from this analysis, sodium reduction would be beneficial when 
baseline sodium is not corrected for.  
 The benefit of a low sodium diet depends on baseline sodium (figure 6). Studies with a 
baseline sodium less than 4000 mg/24 hrs have a pooled HR [95%] of 1.04 [0.95 to 1.13] for 
sodium reduction. Studies with a baseline sodium greater than or equal to 4000 mg/24 hrs have 
a pooled HR [95% CI] of 0.90 [0.82 to 0.98] favoring sodium reduction. This analysis excluded 
the Ekini et al.-201166 study because the study focuses exclusively on a DM2 population and is 
an outlier in this analysis.  
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Figure 5: Relationship between dietary sodium reduction and all cause mortality. Results have 
a pooled HR [95% CI of 1.00 [0.92 to 1.07], indicating no benefit in sodium reduction. I-squared 
of 64.9% indicates moderate variability.  
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Figure 6: All cause mortality when dietary sodium is dichotomized at 4000 mg/24 hrs. Five 
studies with a baseline sodium below 4000 mg/24 hours show no benefit with sodium reduction 
with a pooled HR [95% CI] of 1.04 [0.95 to 1.13]. Five studies with a baseline sodium above 
4000 mg/24 hours show a benefit associated with sodium reduction with a pooled HR [95% CI] 
of 0.90 [0.82 to 0.98]  
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Cardiovascular Disease Mortality:  
 Meta-analysis finds that sodium reduction does not improve CVD mortality risk (figure 7).  
Meta-analysis of 10 studies, that included 101,360 people, found a pooled HR [95% CI] of 0.95 
[0.76 to 1.15] for sodium reduction. The meta-analysis had a high amount of variability 
confirmed by an I-squared of 85.3%. Stratification of data by baseline sodium, age, follow-up, 
and study type does not explain the variability. Removing any one study does not change 
results.  
  He et al.-199954 and Cohen et al.-200853 are not included in the meta-analysis for 
reasons described in the all cause mortality section. Quanitative and qualitative consideration of 
these studies in the analysis does not change results.   
Fatal and Nonfatal Cardiovascular Disease: 
 Meta-analysis finds that sodium reduction does not reduce CVD risk (figure 8). Meta-
analysis of 5 studies, that included 85,252 people, found a pooled RR [95% CI] of 1.00 [0.77 to 
1.12] for sodium reduction at study endpoint. This meta-analysis differs from all others in this 
review because it uses pooled risk ratios since adequate data for hazard ratios are not 
available. Four of the 5 studies favor sodium reduction. However, this review cannot find a valid 
reason to exclude the one study that finds harm in sodium reduction. This meta-analysis is 
heavily influenced by one study, Takachi et al.-201164, because it accounts for 91% of the 
aggregate study population.  
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Figure 7: Relationship between dietary sodium reduction and cardiovascular mortality. CVD 
mortality does not benefit from sodium reduction with a pooled HR [95% CI] of 0.95 [0.76 to 
1.15]. I-squared of 85.3% indicates substantial variability between results.   
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Figure 8: Relationship between dietary sodium reduction and CVD. CVD does not benefit from 
sodium reduction with a pooled RR [95% CI] of 1.00 [0.77 to 1.23] at study endpoint. I-squared 
of 77.3% indicates substantial variability between results. 
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Stroke Mortality:  
 Meta-analysis finds that sodium reduction may reduce stroke mortality risk (figure 9).  
Meta-analysis of 4 studies, that included 104,468 people, found a pooled HR [95% CI] of 0.77 
[0.59 to 0.97] for sodium reduction. The meta-analysis had a high amount of variability 
confirmed by an I-squared of 66.5%. One study shows that the risk of stroke mortality is 
markedly higher in overweight individuals compared to individuals of normal weight, possibly 
helping to explain this variability.54 Mean baseline dietary sodium ranged from 2063 to 5200 
mg/24 hrs indicating a similar benefit across a range of sodium consumptions.  
 Chang et al,-200665 was not included in meta-analysis because the study does not 
provide a HR. However, the study does have a RR [95% CI] of 0.51 [0.240 to 1.18] at 2.6 years, 
which further supports the meta-analysis trend that sodium reduction reduces stroke mortality 
risk.  
Fatal and Non Fatal Stroke:   
 Meta-analysis finds that sodium reduction may reduce stroke risk (figure 10). Meta-
analysis of 4 studies, that included 86,274 people, found a pooled HR [95% CI] of 0.90 [0.84 to 
0.95]. Two studies were not included in the meta-analysis because they lacked hazard ratios. 
The two studies not included in the meta-analysis did not find a significant decrease in stroke 
incidence. The first, Whelton et al.-199868 had a RR [95% CI] of 1.10 [0.47 to 2.57] at 2.5 years. 
The second, Larsson et al.,-200861 did not find a decrease in cerebral ischemia, intracerebral 
hemorrhage, or subarachnoid hemorrhage at a mean of 13.6 years of follow up.  
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Figure 9: Relationship between dietary sodium reduction and stroke mortality. Stroke mortality 
risk appears to decrease with sodium reduction with a pooled HR [95% CI] of 0.77 [0.58 to 
0.97]. I-squared of 66.5 % indicates moderate variability between results. 
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 Figure 10: Relationship between dietary sodium reduction and stroke. Stroke risk appears to 
decrease with sodium reduction with a pooled HR [95% CI] of 0.90 [0.84 to 0.95]. Two studies 
not included in this meta-analysis report stroke as an outcome and do not find benefit in sodium 
reduction.   
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Strength of Evidence 
 Table 7 summarizes strength of evidence for the various outcomes of this review. This 
review finds that all cause mortality, CVD mortality, and CVD does not benefit from decreased 
dietary sodium with low certainty. Analysis depends heavily on prospective cohort studies, 
which are prone to confounding. The influence of baseline dietary sodium and adjustments for 
baseline blood pressure could confound results. The few RCTs that report all cause mortality 
have too little power and too short follow up to draw independent conclusions. The high level of 
inconsistency among studies further weakens certainty. However, these results are 
strengthened by the large number of subjects, directness of the outcome on patient health, and 
the high precision of the pooled risk estimate.  
 This review finds that stroke and stroke mortality benefit from dietary sodium reduction 
with low certainty. Weak study types, the potential for confounding, inconsistent results weaken 
certainty. The large number of subjects and direct outcomes strengthen these results. 
Furthermore, it is reassuring that the reduction of risk is observed in both stroke and stroke 
mortality. Notably, none of the 5 studies included in the stroke mortality analysis are present in 
the total fatal/nonfatal stroke analysis. Thus, 11 unique studies generally agree that sodium 
reduction decreases stroke risk.   
   
  
36 
 
Table 7: Strength of Evidence Table 
 
Domains pertaining to strength of evidence 
Magnitude of 
effect 
Strength of 
evidence 
Number of 
Studies; 
Number of 
Subjects 
Risk of Bias; 
Design/ 
Quality 
Consistency 
 
(consistent or 
inconsistent) 
Directness 
 
(Direct or 
Indirect) 
Precision 
 
(Precise or 
Imprecise) 
Confounding 
 
(present or 
absent) 
Summary 
Effect Size 
(95% CI) 
High, 
Moderate, 
Low, 
Insufficient 
All Cause Mortality 
14; 53378 Moderate; 
Prospective 
Cohorts and 
RCTs/Good 
and Fair 
Inconsistent Direct Precise Present Pooled Hazard 
Ratio: 
1.00 (0.92 to 
1.07) 
Low 
Cardiovascular Disease Mortality 
12; 101360 Moderate; 
Prospective 
Cohorts and 
RCTs/Good 
and Fair 
Inconsistent Direct Precise Present Pooled Hazard 
Ratio:  
0.95 [0.76 to 
1.15] 
Low 
Fatal and Nonfatal Cardiovascular Disease 
5; 85282 Moderate; 
Prospective 
Cohorts and 
RCTs/Good 
and Fair 
Inconsistent Direct Precise Present Pooled Risk 
Ratio:  
1.00 [0.77 to 
1.12] 
Low 
Stroke Mortality 
5; 106450 Moderate; 
Prospective 
Cohorts and 
RCT/ Fair 
Inconsistent Direct Precise Present Pooled Hazard 
Ratio:  
0.77 [0.59 to 
0.97] 
Low 
Fatal and Nonfatal Stroke 
6; 113805 Moderate; 
Prospective 
Cohorts and 
RCTs/Good 
and Fair 
Inconsistent Direct Precise Present Pooled Hazard 
Ratio:  
0.90 [0.84 to 
0.95] 
Low 
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Applicability 
 The results of this systematic review apply broadly to the general population. Diabetics 
and overweight individuals are specific subpopulations represented in this report. This review 
includes population representative levels of females and non-whites. This review does not apply 
to individuals who have specific medical problems. This review excluded records that focused 
on secondary prevention populations. These results apply to all age groups and up to 20 years 
of follow up. These results apply to a maximum of approximately 2000 mg per day reduction in 
dietary sodium. The mean baseline dietary sodium levels in this review ranged between 2000 
and 5000 mg per day.   
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DISCUSSION 
 The primary conclusion of this review is that that reducing dietary sodium does not 
decrease all cause mortality with low certainty. This review secondarily concludes that 
reductions in dietary sodium do not, cardiovascular mortality, or cardiovascular risk with low 
certainty. Stroke and stroke mortality appear to decrease with low sodium diets with low 
certainty. This review believes that all cause mortality is the best outcome because more 
studies report all cause mortality than any other outcomes. Furthermore, all cause mortality is 
not prone to ICD reporting biases. Studies have shown that ICD codes are moderately 
inaccurate.72,73 Furthermore, aggregate outcomes like cardiovascular disease and stroke are 
often incapable of distinguishing clinically significant and clinically insignificant disease. This 
systematic review additionally abstracted specific CVD events like myocardial infarction (MI) 
and congestive heart failure (CHF). However, specific causes of CVD, like MI and CHF, are very 
rarely reported in the included studies.  
 This systematic review includes 248,895 unique individuals. Seventeen out of the 20 
included studies have a follow-up greater than 5 years. Half of the included studies have a 
follow up over 10 years. Thus, it is unlikely that any future prospective cohort studies will 
singularly change these results. However, It is difficult to draw firm conclusions because much 
variability exists between studies.  
 The risk for confounding plays a major role in creating uncertainty. Prospective cohort 
studies contribute to 97% of this review’s aggregate study population. As such the risk for 
confounding cannot be eliminated. Confounding likely contributes to the high degree of 
interstudy variability. As an example, two studies report on the same NHANES III cohort. The 
NHANES III cohort was a nationally representative sample of nutritional intake in older, non-
institutionalized Americans.74,75 One study found that a 1000 mg/24 hours increase in dietary 
sodium decreased all cause mortality HR [95% CI] 0.94 [0.88 to 1.01] in the NHANES III 
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cohort.53 The second study found that a 1000 mg/24 hours increase in dietary sodium increased 
all cause mortality HR [95% CI] 1.20 [1.03 to 1.41] in the NHANES III cohort.57 Some have 
proposed that the difference in these two findings occurs because one study corrects for 
baseline potassium and the other does not.76 I believe the more important point is that one 
simple statistical adjustment, or one single confounder, is capable of completely changing the 
conclusions of a study.  
 Adjustments for baseline blood pressure may confound results observed in prospective 
cohort studies. Adjustment for baseline blood pressure removes the mechanism by which 
sodium likely causes harm. Thus, studies that correct for baseline blood pressure are assessing 
for an independent association between dietary sodium and outcomes. It wouldn’t be surprising 
to find that dietary sodium is not associated with harm independent of blood pressure. However, 
prospective cohort studies that do not correct baseline blood pressure open up the potential for 
blood pressure confounding. It is impossible to know what degree of blood pressure is 
associated with sodium and what percent is due to other causes. Only randomized controlled 
trials can control for blood pressure confounding without removing the mechanism by which 
sodium causes harm.  
 The efficacy of lowering dietary sodium likely depends on baseline dietary sodium levels. 
This review shows that when population dietary sodium is above 4000 mg/24 hrs, sodium 
reduction reduces all cause mortality. However, this review does not suggest that 4000 mg/ 24 
hrs is the ideal sodium intake. This review lacks sufficient data to generate a dose-response 
relationship between dietary sodium and healthcare risk.  
 Two studies report a “j-shaped” dose-response relationship between dietary sodium and 
risk (figure 11).38,60  These two studies show that both high and low sodium levels are 
associated with harm. The first report suggests that all cause mortality risk is lowest between 
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2.2 to 4.0 grams of urinary sodium per day.60 The second report suggests that that composite 
risk of cardiovascular death, stroke, myocardial infarction, and hospitalization for congestive 
heart failure is lowest between 4.1 to 5.9 grams of urinary sodium per day.38 
   
Figure 11: J-shaped relationship between dietary sodium and hazard ratios.  
 Graph A represents a DM1 population and shows that risk of all cause mortality 
is lowest at urine sodium excretion between 2.2 and 4.0 grams per day.60 
 Graph B represents a population with pre-existing CVD and shows that 
composite risk of Cardiovascular Death, Stroke, Myocardial Infarction, and 
Hospitalization for Congestive Heart Failure is lowest at urine sodium excretion 
between 4.1 to 5.9 grams per day.38 
 Graph A is adapted from Thomas MC, Moran J, Forsblom C, et al. The 
association between dietary sodium intake, ESRD, and all-cause mortality in 
patients with type 1 diabetes. Diabetes care. Apr 2011;34(4):861-866.60 
 O'Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion 
and risk of cardiovascular events. JAMA : the journal of the American Medical 
Association. 2011;306(20):2229-2238.38 
 
 This review does not support current recommendations to reduce dietary sodium as 
outlined in table 1. All cause mortality analysis did not identify any benefit of dietary sodium 
below 4000 mg/day. Two studies identified in figure 11 corroborate this view, suggesting ideal 
sodium levels well above recommended values. Furthermore, both studies in figure 11 are high 
risk populations in whom aggressive sodium reduction is often recommended. Though only 2 
imperfect studies, figure 11 raises the potential for harm should populations actually achieve 
recommended sodium consumption levels. Additionally, most recommendations suggest levels 
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of sodium that should not be exceeded. However, recommendations should also try to identify a 
minimum level of sodium that populations should remain above.   
 At a policy level this review does not support systematic programs to decrease 
population wide sodium consumption for three reasons. First, this review found that sodium 
reduction does not benefit all cause mortality. While this review does conclude that sodium 
reduction reduces stroke risk, this review cannot determine if the stroke benefit improves quality 
of life in the setting of unchanged all cause mortality. Second, many studies in this review 
indicate that low sodium may increase mortality. In a setting where the benefits of sodium 
reduction are uncertain, and the potential for harm are legitimate, more research should be 
conducted before policy is undertaken. Third, only one study included in the synthesis portion of 
this review provides a dose response relationship between dietary sodium and outcomes.60 A 
dose response relationship is necessary to identify an ideal level of sodium intake. Without a 
clear dose response relationship, sodium reduction policy will not have any clear goals.  
 This review does conclude that sodium reduction would likely decrease stroke risk. 
However, the practical application of this conclusion is uncertain. The only study that 
prospectively evaluated cases for stroke did not find a benefit to sodium reduction RR [95% CI] 
of 1.10 [0.47 to 2.57] at 2.5 years.68 All other studies diagnose stroke through ICD codes, which 
do not distinguish different types or severities of stroke. However, a majority of studies do 
suggest that sodium reduction decreases stroke, as borne out in the meta-analysis. 
Furthermore, these prospective stroke outcomes are corroborated by cross-sectional studies 
that show a positive relationship between stroke and dietary sodium.31 At a population level, I 
find it difficult to evaluate the relative quality of life benefit in reducing ICD diagnosed stroke 
when all cause mortality is unchanged. 
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 This systematic review identifies the need for a large, long term trial to assess the 
efficacy of dietary sodium reduction. The high interstudy variability and risk for confounding 
make the relationship between dietary sodium and patient-centric outcomes uncertain. Such a 
trial should contain sufficient power to determine a dose-response relationship between dietary 
sodium and mortality, CVD, and stroke. Patient outcomes should be prospectively identified in a 
masked way so as to only gather clinically significant outcomes. Furthermore, such a trial 
should include quality of life measures to assess the relative value of morbidity reductions in the 
setting of unchanged all cause mortality.  
 As a corollary, this systematic review sought to determine why 2 previous systematic 
reviews had opposing conclusion about the efficacy of sodium reduction. One review included 
all prospective studies and concluded that increased dietary sodium increased the risk of 
cardiovascular disease and stroke.34 A second review of only RCTs concluded that there was 
insufficient evidence to conclude that dietary sodium is associated with all cause or CVD 
mortality.35 The two studies differ because the second review has a much smaller aggregate 
study population since it only includes RCTs. However, the two studies also are reporting on 
two slightly different outcomes. The first review aggregates fatal and non-fatal cardiovascular 
events, while the second study only considers cardiovascular mortality. This further decreases 
the power of the second review because it is looking at a rarer outcome.  
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 The results of this review differ from the previous systematic reviews. Since the last 
systematic reviews were published, 6 prospective cohort studies of dietary sodium have been 
published. These 6 new studies make 100,550 new people available for analysis, effectively 
doubling the power of this current systematic review. Two of these new studies show statistically 
significant harm associated with sodium reduction. Furthermore, a previous systematic review 
included poor quality cohort studies in their data synthesis. For example, one included study 
qualitatively estimated high sodium intake by asking if individuals ate “salty food”, and found a 
positive association between salty food consumption and stroke with a RR [95% CI] of 1.79 
[1.18-2.71].77 These poor quality data were subsequently included in other meta-analyses.34 
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SUPPLEMENTAL FIGURES:  
 Supplemental Figure 1: All Cause Mortality Forest Plot Organized by Method of Sodium 
Estimation 
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 Supplemental Figure 2: All Cause Mortality Forest Plot Organized by Baseline Age 
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 Supplemental Figure 3: All Cause Mortality Forest Plot Organized by Follow-up Duration 
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 Supplemental Figure 4: All Cause Mortality Forest Plot Organized by Magnitude of Dietary 
Sodium Reduction 
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 Supplemental Figure 5: All Cause Mortality Forest Plot Organized by Correction of Blood 
Pressure at Individual Study Baseline
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